Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Mogrify, Ltd.
Finance Watch: Dyno Therapeutics Raises $100m For Novel AAV Vectors
Private Company Edition: Dyno’s first VC round will enable more deals for its novel AAV platform; Eikon pioneers new drug discovery technology. Also, Treeline’s early funding revealed at $211.7m; Capsida raised $140m from a VC round, AbbVie deal; and Affinia closed a $110m series B round.
Mogrify: Using Big Data To Transform Development Of Cell Therapies
Money in the bank, biotech legacies onboard, a fresh partnership, an emerging internal cell therapy pipeline and a grand vision for the broad-scale application of its technology – has Mogrify got it all? The biotech’s chief business officer, Karin Schmitt, talks to In Vivo about the group’s near- and long-term goals.
AstraZeneca Veteran Returns To Biotech With Fresh Goals For A New Decade
In December 2019, Jane Osbourn became the first woman to win Scrip’s Life Time Achievement Award for her work in human monoclonal antibody drug research.
AstraZeneca And Galapagos Shine At The 15th Annual Scrip Awards
The pharma, biotech and allied industries came together in London on 4 December to celebrate another year of achievement at the 15th Annual Scrip Awards, hosted by the broadcaster Fiona Bruce.
- Gene Therapy, Cell Therapy
Drug Discovery Tools
- Other Names / Subsidiaries
- Cell Mogrify Ltd
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.